Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Dose-finding in oncology
- Dose lmiting toxicity (DLT)
- The maximum tolerable dose (MTD)
- Dose-toxicity relationship
- Starting dose and dose level selection
- Traditional or 3+3 design (1)
- Traditional or 3+3 design (2)
- Operating characteristics of 3+3 design
- Advantages and disadvantages of the 3+3 design
- A+B designs
- A+B designs: definition
- A+B designs: how to construct
- A+B designs: examples
- Trials with the MTD defined using toxicity grades
- Defining MTD using toxicity grades: example (1)
- Defining MTD using toxicity grades: example (2)
- Defining MTD using toxicity grades: example (3)
- A summary
- Escalation vs. fixed sample size designs for trials
- Fixed sample size vs. A+B designs: which to use?
- Fixed sample size designs
- Continual reassessment method (CRM)
- Cumulative cohort design (CCD) to find the MTD
- Components of the CRM and CCD
- Start-up rule (1)
- Start-up rule (2)
- Estimation of MTD after cumulative cohort design
- Design modifications for delayed toxicity outcomes
- Oncology trial with delayed toxicity outcomes (1)
- Oncology trial with delayed toxicity outcomes (2)
- Oncology trial with delayed toxicity outcomes (3)
- An example of a phase I trial with two agents
- An example of a phase I trial with ordered groups
- Single vs. separate trials
- Bayesian designs for 2 agents/ordered groups trial
- Isotonic designs for 2 agents/ordered group trials
- References (1)
- References (2)
- References (3)
- Additional reading
Topics Covered
- Maximum tolerable dose
- Standard or 3+3 design
- A+B designs
- Phase I trials that use toxicity grades
- Escalation versus fixed sample size designs for dose-finding trials
- Continual reassessment method
- Cumulative cohort design
- Start-up rule
- Design modifications for delayed toxicity outcomes
- Trials with two agents and ordered groups
Links
Series:
Categories:
Talk Citation
Ivanova, A. (2007, October 1). Dose-finding trials in oncology [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 13, 2024, from https://doi.org/10.69645/NZDG2139.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Anastasia Ivanova has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.